Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Press Release
Article
Camber Pharmaceuticals Announces Addition of Eslicarbazepine Acetate Tablets
Key Takeaways
- Eslicarbazepine Acetate Tablets target partial-onset seizures in patients aged four and older, broadening treatment options.
- Available strengths include 200 mg, 400 mg, and 800 mg in 30-count bottles, and 600 mg in a 60-count bottle.
Camber Pharmaceuticals is excited to announce the addition of Eslicarbazepine Acetate Tablets to its portfolio.
Eslicarbazepine Acetate Tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Eslicarbazepine Acetate Tablets are available in:
- 200 mg, 400 mg, and 800 mg strengths in 30-count bottles
- 600 mg strength in a 60-count bottle
To find out more information on Eslicarbazepine Acetate Tablets, please visit:www.camberpharma.com/eslicarbazepine
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Videos
Related Content
